Fatigue - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Fatigue - Pipeline Review, H1 2015', provides an overview of the Fatigue's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fatigue - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fatigue and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fatigue pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fatigue - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Fatigue Overview 5 Therapeutics Development 6 Pipeline Products for Fatigue - Overview 6 Pipeline Products for Fatigue - Comparative Analysis 7 Fatigue - Therapeutics under Development by Companies 8 Fatigue - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Fatigue - Products under Development by Companies 12 Fatigue - Companies Involved in Therapeutics Development 13 Biovista Inc. 13 Dimerix Bioscience Pty Ltd 14 Hemispherx Biopharma, Inc. 15 Merz Pharmaceuticals GmbH 16 MultiCell Technologies, Inc. 17 PharmaLundensis AB 18 Teva Pharmaceutical Industries Limited 19 Fatigue - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Fatigue - Dormant Projects 30 Fatigue - Product Development Milestones 31 Featured News & Press Releases 31 Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Number of Products under Development for Fatigue, H1 2015 6 Number of Products under Development for Fatigue - Comparative Analysis, H1 2015 7 Number of Products under Development by Companies, H1 2015 8 Comparative Analysis by Late Stage Development, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Fatigue - Pipeline by Biovista Inc., H1 2015 13 Fatigue - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 14 Fatigue - Pipeline by Hemispherx Biopharma, Inc., H1 2015 15 Fatigue - Pipeline by Merz Pharmaceuticals GmbH, H1 2015 16 Fatigue - Pipeline by MultiCell Technologies, Inc., H1 2015 17 Fatigue - Pipeline by PharmaLundensis AB, H1 2015 18 Fatigue - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Assessment by Combination Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Fatigue - Dormant Projects, H1 2015 30
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.